CMV-SpCas9HF AAV (Serotype 9)

CMV-SpCas9HF AAV (serotype 9) represents an advanced system for gene editing and therapy that leverages CRISPR-Cas9 technology and the adeno-associated virus (AAV) vector platform. SpCas9HF is a high-fidelity variant of the Cas9 nuclease engineered to minimize off-target effects, thereby increasing its precision in gene editing applications. A CMV promoter is used to drive expression of SpCas9HF, ensuring efficient gene targeting within host cells.

AAV serotype 9 is of interest for its ability to efficiently transfect a wide range of cell types, both dividing and non-dividing, making it a reliable choice for in vivo applications. It has broad tissue tropism, particularly the ability to penetrate the blood-brain barrier, making it valuable in neurological research and therapy. The combination of these elements makes CMV-SpCas9HF AAV (serotype 9) a powerful tool for research and potential therapeutic interventions aimed at precisely altering genes with reduced risk of unintended genome modifications. The system's applications range from basic research to clinical applications, providing opportunities to advance the treatment of genetic diseases, including those affecting the central nervous system.